Skip to main content
Fig. 5 | Trials

Fig. 5

From: Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)

Fig. 5

Algorithm for administration of INX NOR-DRUM A (visits ≥ 14 weeks) and NOR-DRUM B, intervention group. ADAb anti-drug antibody(ies), ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, CD Crohn’s disease, DAS28 Disease Activity Score using 28 joints, HBI Harvey-Bradshaw Index, INX infliximab, PASI Psoriasis Area and Severity Index, PsA psoriatic arthritis, RA rheumatoid arthritis, SpA spondyloarthritis, UC ulcerative colitis

Back to article page

Trials

ISSN: 1745-6215